194
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Assessing regulated cell death modalities as an efficient tool for in vitro nanotoxicity screening: a review

ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon
Pages 218-248 | Received 07 Jul 2022, Accepted 11 Apr 2023, Published online: 21 Apr 2023
 

Abstract

Nanomedicine is a fast-growing field of nanotechnology. One of the major obstacles for a wider use of nanomaterials for medical application is the lack of standardized toxicity screening protocols for assessing the safety of newly synthesized nanomaterials. In this review, we focus on less frequently studied nanomaterials-induced regulated cell death (RCD) modalities, including eryptosis, necroptosis, pyroptosis, and ferroptosis, as a tool for in vitro nanomaterials safety evaluation. We summarize the latest insights into the mechanisms that mediate these RCDs in response to nanomaterials exposure. Comprehensive data from reviewed studies suggest that ROS (reactive oxygen species) overproduction and ROS-mediated pathways play a central role in nanomaterials-induced RCDs activation. On the other hand, studies also suggest that individual properties of nanomaterials, including size, shape, or surface charge, could determine specific toxicity pathways with consequent RCD induction as well. We anticipate that the evaluation of RCDs can become one of the mechanism-based screening methods in nanotoxicology. In addition to the toxicity assessment, evaluation of necroptosis-, pyroptosis-, and ferroptosis-promoting capacity of nanomaterials could simultaneously provide useful information for specific medical applications as could be their anti-tumor potential. Moreover, a detailed understanding of molecular mechanisms driving nanomaterials-mediated induction of immunogenic RCDs will substantially aid novel anti-tumor nanodrugs development.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This research was supported by the Ministry of Health of Ukraine as a fragment of the project entitled ‘Research of Effectiveness, Mechanisms of Action and Safety of Rare-Earth Orthovanadate Nanoparticles for Optimization of Radiation Therapy in Oncopathology’ (state registration number 0121U110920), by the Charles University in Prague, Czech Republic (PRIMUS/17/MED/9, UNCE/MED/016, Cooperation), and the Czech National Institute for Cancer Research (reg. No. LX22NPO5102).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.